TY - JOUR
T1 - Intrasubunit and intersubunit steroid binding sites independently and additively mediate a1b2c2L GABAA receptor potentiation by the endogenous neurosteroid allopregnanolone
AU - Germann, Allison L.
AU - Pierce, Spencer R.
AU - Tateiwa, Hiroki
AU - Sugasawa, Yusuke
AU - Reichert, David E.
AU - Evers, Alex S.
AU - Steinbach, Joe Henry
AU - Akk, Gustav
N1 - Publisher Copyright:
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Prior work employing functional analysis, photolabeling, and X-ray crystallography have identified three distinct binding sites for potentiating steroids in the heteromeric GABAA receptor. The sites are located in the membrane-spanning domains of the receptor at the b-a subunit interface (site I) and within the a (site II) and b subunits (site III). Here, we have investigated the effects of mutations to these sites on potentiation of the rat a1b2c2L GABAA receptor by the endogenous neurosteroid allopregnanolone (3a5aP). The mutations were introduced alone or in combination to probe the additivity of effects. We show that the effects of amino acid substitutions in sites I and II are energetically additive, indicating independence of the actions of the two steroid binding sites. In site III, none of the mutations tested reduced potentiation by 3a5aP, nor did a mutation in site III modify the effects of mutations in sites I or II. We infer that the binding sites for 3a5aP act independently. The independence of steroid action at each site is supported by photolabeling data showing that mutations in either site I or site II selectively change steroid orientation in the mutated site without affecting labeling at the unmutated site. The findings are discussed in the context of linking energetic additivity to empirical changes in receptor function and ligand binding. SIGNIFICANCE STATEMENT Prior work has identified three distinct binding sites for potentiating steroids in the heteromeric c-aminobutyric acid type A receptor. This study shows that the sites act independently and additively in the presence of the steroid allopregnanolone and provide estimates of energetic contributions made by steroid binding to each site.
AB - Prior work employing functional analysis, photolabeling, and X-ray crystallography have identified three distinct binding sites for potentiating steroids in the heteromeric GABAA receptor. The sites are located in the membrane-spanning domains of the receptor at the b-a subunit interface (site I) and within the a (site II) and b subunits (site III). Here, we have investigated the effects of mutations to these sites on potentiation of the rat a1b2c2L GABAA receptor by the endogenous neurosteroid allopregnanolone (3a5aP). The mutations were introduced alone or in combination to probe the additivity of effects. We show that the effects of amino acid substitutions in sites I and II are energetically additive, indicating independence of the actions of the two steroid binding sites. In site III, none of the mutations tested reduced potentiation by 3a5aP, nor did a mutation in site III modify the effects of mutations in sites I or II. We infer that the binding sites for 3a5aP act independently. The independence of steroid action at each site is supported by photolabeling data showing that mutations in either site I or site II selectively change steroid orientation in the mutated site without affecting labeling at the unmutated site. The findings are discussed in the context of linking energetic additivity to empirical changes in receptor function and ligand binding. SIGNIFICANCE STATEMENT Prior work has identified three distinct binding sites for potentiating steroids in the heteromeric c-aminobutyric acid type A receptor. This study shows that the sites act independently and additively in the presence of the steroid allopregnanolone and provide estimates of energetic contributions made by steroid binding to each site.
UR - http://www.scopus.com/inward/record.url?scp=85110704623&partnerID=8YFLogxK
U2 - 10.1124/MOLPHARM.121.000268
DO - 10.1124/MOLPHARM.121.000268
M3 - Article
C2 - 33958479
AN - SCOPUS:85110704623
SN - 0026-895X
VL - 100
SP - 19
EP - 31
JO - Molecular pharmacology
JF - Molecular pharmacology
IS - 1
ER -